DB:HPR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.


Snowflake Analysis

Solid track record and good value.


Similar Companies

Share Price & News

How has Horizon Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HPR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.5%

HPR

-5.6%

DE Pharmaceuticals

-3.6%

DE Market


1 Year Return

137.8%

HPR

8.1%

DE Pharmaceuticals

3.7%

DE Market

Return vs Industry: HPR exceeded the German Pharmaceuticals industry which returned 8.1% over the past year.

Return vs Market: HPR exceeded the German Market which returned 3.8% over the past year.


Shareholder returns

HPRIndustryMarket
7 Day4.5%-5.6%-3.6%
30 Day8.7%-8.6%-2.0%
90 Day67.4%1.1%13.3%
1 Year137.8%137.8%11.6%8.1%6.0%3.7%
3 Yearn/a27.7%12.8%1.1%-6.9%
5 Year82.9%82.9%19.9%-0.8%7.8%-6.8%

Price Volatility Vs. Market

How volatile is Horizon Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Horizon Therapeutics undervalued compared to its fair value and its price relative to the market?

48.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HPR (€53.27) is trading below our estimate of fair value (€103.17)

Significantly Below Fair Value: HPR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HPR is good value based on its PE Ratio (19.3x) compared to the DE Pharmaceuticals industry average (21.1x).

PE vs Market: HPR is good value based on its PE Ratio (19.3x) compared to the German market (20.9x).


Price to Earnings Growth Ratio

PEG Ratio: HPR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: HPR is overvalued based on its PB Ratio (5.3x) compared to the DE Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is Horizon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-40.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HPR's earnings are forecast to decline over the next 3 years (-40.7% per year).

Earnings vs Market: HPR's earnings are forecast to decline over the next 3 years (-40.7% per year).

High Growth Earnings: HPR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: HPR's revenue (16.6% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: HPR's revenue (16.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HPR's Return on Equity is forecast to be high in 3 years time (30.5%)


Next Steps

Past Performance

How has Horizon Therapeutics performed over the past 5 years?

31.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HPR has a large one-off loss of $65.3M impacting its March 31 2020 financial results.

Growing Profit Margin: HPR's current net profit margins (43.1%) are higher than last year (6.1%).


Past Earnings Growth Analysis

Earnings Trend: HPR has become profitable over the past 5 years, growing earnings by 31.1% per year.

Accelerating Growth: HPR's earnings growth over the past year (663%) exceeds its 5-year average (31.1% per year).

Earnings vs Industry: HPR earnings growth over the past year (663%) exceeded the Pharmaceuticals industry 15.8%.


Return on Equity

High ROE: HPR's Return on Equity (27.1%) is considered high.


Next Steps

Financial Health

How is Horizon Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: HPR's short term assets ($1.4B) exceed its short term liabilities ($592.4M).

Long Term Liabilities: HPR's short term assets ($1.4B) do not cover its long term liabilities ($1.5B).


Debt to Equity History and Analysis

Debt Level: HPR's debt to equity ratio (62.1%) is considered high.

Reducing Debt: HPR's debt to equity ratio has reduced from 85.9% to 62.1% over the past 5 years.

Debt Coverage: HPR's debt is well covered by operating cash flow (22.6%).

Interest Coverage: HPR's interest payments on its debt are not well covered by EBIT (1.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Horizon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HPR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HPR's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Tim Walbert (53 yo)

12.17yrs

Tenure

US$13,873,171

Compensation

Mr. Timothy P. Walbert, also known as Tim, serves as Chairman of the Board at Exicure, Inc. since April 2020. Mr. Walbert serves as Lead Independent Director at Assertio Holdings, Inc. from May 19, 2020. M ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD13.87M) is above average for companies of similar size in the German market ($USD5.26M).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Walbert
Chairman12.17yrsUS$13.87m0.45%
$ 44.3m
Paul Hoelscher
Executive VP & CFO5.83yrsUS$4.44m0.069%
$ 6.9m
Barry Moze
Executive VP & Chief Administrative Officer0.58yrUS$4.66m0.093%
$ 9.2m
Vikram Karnani
Executive VP & Chief Commercial Officerno dataUS$4.06m0.022%
$ 2.2m
Miles McHugh
Chief Accounting Officer & Senior VP5.67yrsno data0.018%
$ 1.7m
Tina Ventura
Senior Vice President of Investor Relationsno datano datano data
Brian Beeler
Executive VP & General Counsel5.25yrsno data0.019%
$ 1.9m
Timothy Ayers
Chief Compliance Officer & VP5.25yrsno datano data
Geoffrey Curtis
Executive VP of Corporate Affairs & Chief Communications Officer4.67yrsno data0.018%
$ 1.8m
Irina Konstantinovsky
Executive VP & Chief Human Resources Officer2.92yrsUS$2.31m0.019%
$ 1.8m
Jeffrey Sherman
Executive VP & Chief Medical Officerno dataUS$916.28k0.15%
$ 15.2m
Joe Whalen
Senior Vice President of Business Development & Alliance Management7.42yrsno datano data

5.3yrs

Average Tenure

53yo

Average Age

Experienced Management: HPR's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Walbert
Chairman12.17yrsUS$13.87m0.45%
$ 44.3m
Michael Grey
Lead Independent Director8yrsUS$524.03k0.033%
$ 3.2m
William Daniel
Independent Director5.92yrsUS$502.76k0.035%
$ 3.4m
Jeff Himawan
Director13.08yrsUS$521.33k0.022%
$ 2.2m
Gino Santini
Independent Director8.42yrsUS$518.83k0.021%
$ 2.0m
H. Watkins
Independent Director6.33yrsUS$515.22k0.040%
$ 3.9m
James Shannon
Independent Director3yrsUS$507.24k0.015%
$ 1.5m
Susan Mahony
Independent Director1yrUS$341.79k0.0038%
$ 377.9k
Pascale Witz
Independent Director3yrsUS$494.61k0.016%
$ 1.5m

6.3yrs

Average Tenure

63yo

Average Age

Experienced Board: HPR's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HPR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.


Top Shareholders

Company Information

Horizon Therapeutics Public Limited Company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Horizon Therapeutics Public Limited Company
  • Ticker: HPR
  • Exchange: DB
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$11.674b
  • Listing Market Cap: US$9.868b
  • Shares outstanding: 190.78m
  • Website: https://www.horizontherapeutics.com

Number of Employees


Location

  • Horizon Therapeutics Public Limited Company
  • Connaught House
  • 1st Floor
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HZNPNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2011
HPRDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2011

Biography

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic disease ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/02 21:56
End of Day Share Price2020/07/31 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.